Diarrhea with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: A meta-analysis of randomized controlled trials
Author:
Funder
Fundamental Research Funds for the Central Universities, Southwest Minzu University
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference40 articles.
1. A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-lineplatinum-doublet chemotherapy;Ahn;Lung Cancer,2013
2. Phase II study of vandetanib or placebo in small-cell lung Cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada clinical trials group study BR.20;Arnold;J. Clin. Oncol.,2007
3. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy;Awada;Ann. Oncol.,2013
4. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer;Burstein;J. Clin. Oncol.,2010
5. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study;Cappuzzo;Lancet Oncol.,2010
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Management and Mechanisms of Diarrhea Induced by Tyrosine Kinase Inhibitors in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer;Cancer Control;2024-01
2. Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study;Targeted Oncology;2023-06-17
3. Clinical uses and safety concerns of tyrosine kinase inhibitors with a focus on novel drugs: A narrative review;Journal of Oncology Pharmacy Practice;2023-05-12
4. Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma;Therapeutic Advances in Medical Oncology;2023-01
5. Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis;Critical Reviews in Oncology/Hematology;2021-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3